Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for injection clinical trials

A Phase I/III, Multi-center, Randomized, Double-blind Study of BAT3306 plus Chemotherapy versus Keytruda® plus Chemotherapy to Evaluate Pharmacokinetics, Efficacy, and Safety in Participants with Stage IV Non-squamous Non-small Cell Lung Cancer.

This study is testing a new drug (BAT3306) against an existing one (Keytruda®) in people with advanced non-small cell lung cancer. Both drugs are given with standard chemotherapy. We want to see how safe and effective the new drug is, and how it acts in the body.